Mechanistic anti-cancer assays were performed on Compound 2, revealing noteworthy changes such as MMP reduction, increase in ROS production, inhibition of anti-apoptotic protein BCL-2, and activation of BAX and caspase-3. This evidence concerns the gene BCL2 and cancer.